<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892980</url>
  </required_header>
  <id_info>
    <org_study_id>ISI dV Xi-NSM</org_study_id>
    <nct_id>NCT03892980</nct_id>
  </id_info>
  <brief_title>Da Vinci Xi NSM IDE Study</brief_title>
  <official_title>A Prospective, Multicenter Investigation of the da Vinci® Xi™ Surgical System in Nipple Sparing Mastectomy (NSM) Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and effectiveness of the da Vinci Xi Surgical System in
      Nipple Sparing Mastectomy procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical management for breast cancer and risk-reducing techniques have evolved from radical
      mastectomy to other techniques such as nipple and skin sparing procedures. Nipple-sparing
      mastectomy (NSM) with reconstruction technology offers the opportunity to preserve the shape
      of both the breast and the nipple-areola complex.

      This study will evaluate the safety and effectiveness of the da Vinci Xi Surgical System in
      NSM procedures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects undergo nipple-sparing mastectomy (NSM) procedures using the da Vinci Xi Surgical System</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness: No conversions to open NSM</measure>
    <time_frame>Assessed during surgery</time_frame>
    <description>Conversion is defined as conversion of da Vinci Xi robotic-assisted surgery to open surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety: Incidence of adverse events</measure>
    <time_frame>Assessed during surgery to 42 days after surgery</time_frame>
    <description>Incidence of intraoperative and post-operative procedure and device-related adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Nipple Sparing Mastectomy</condition>
  <arm_group>
    <arm_group_label>Nipple Sparing Mastectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nipple-Sparing Mastectomy</intervention_name>
    <description>Nipple-sparing mastectomy using da Vinci Xi Surgical System.</description>
    <arm_group_label>Nipple Sparing Mastectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between ages 18-80.

          -  BMI ≤ 29.

          -  Candidate for an NSM procedure.

          -  At increased risk for breast cancer and is seeking prophylactic NSM surgery.

          -  Breast ptosis ≤ Grade 2.

          -  Cup size ≤ C.

          -  No presence of occult cancer as confirmed by physical exam and by preoperative imaging
             per institution's guidelines.

        Exclusion Criteria:

          -  Current or prior history of ipsilateral in-situ or invasive breast carcinoma.

          -  Previous breast surgery of the ipsilateral breast

          -  Current history of smoking or has smoked within 1 year of screening.

          -  Skin conditions

          -  Uncontrolled diabetes mellitus.

          -  Previous chemotherapy or radiation

          -  High risk for anesthesia or significant medical comorbidities

          -  Contraindicated for general anesthesia or surgery.

          -  Known bleeding or clotting disorder.

          -  Pregnant or suspected to be pregnant or is lactating.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Virk</last_name>
    <phone>4085234758</phone>
    <email>NSM-Xi@intusurg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

